Comparative Studies of Biosimilar Medicinal Products

Comparative Studies of Biosimilar Medicinal Products

The article describes specific aspects of biosimilars research and development. The aim of the study was to analyse the ways to conduct comparative studies of biotechnological medicinal products and the main approaches to the assessment of the obtained data. The paper highlights that biotechnologica...

Full description

Bibliographic Details
Main Author:	O. B. Talibov
Format:	Article
Language:	Russian
Published:	Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’) 2019-06-01
Series:	Регуляторные исследования и экспертиза лекарственных средств
Subjects:	biotechnological medicinal products monoclonal antibodies biosimilars microheterogeneity post-translational modification pharmacokinetics pharmacodynamics clinical trials
Online Access:	https://www.vedomostincesmp.ru/jour/article/view/229

Similar Items

Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
by: V. V. Smirnov, et al.
Published: (2023-06-01)

Results of the Estimation of Biosimilarity of RinLiz<sup>®</sup> (LLC «GEROPHARM», Russia) and Humalog<sup>®</sup> (Lilly France, France) Using the Method of the Hyperinsulinemic Eulygemic Clamp on Healthy Voluntary
by: A. Yu. Mayorov, et al.
Published: (2020-05-01)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
by: Yiya Wang, et al.
Published: (2022-08-01)

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
by: Igor Makarenko, et al.
Published: (2023-10-01)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021-04-01)

REGULATORY CONSIDERATIONS OF BIOSIMILARS AND CLINICAL DILEMA OF THEIR USE
by: Sonja Genadieva Stavrik, et al.
Published: (2017-04-01)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
by: Hanjing Chen, et al.
Published: (2022-01-01)

A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects
by: Yanhua Ding, et al.
Published: (2023-10-01)

Biosimilars for Haematologic Malignancies: The Path to Sustainable Care
by: Paul Cornes, et al.
Published: (2017-08-01)

Review of the textbook “Clinical and pharmacological characteristics of biotechnological drugs: from classifications to adverse events”
by: V. I. Petrov
Published: (2024-04-01)

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
by: Jin Wang, et al.
Published: (2019-08-01)

First available biosimilar monoclonal antibodies
by: Zh. I. Avdeeva, et al.
Published: (2018-02-01)

Mechanistic considerations for the use of monoclonal antibodies for cancer therapy
by: Patrick M. Glassman, et al.
Published: (2014-03-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies
by: Yaru Yang, et al.
Published: (2024-10-01)

Alteration of Transthyretin Microheterogeneity in Serum of Multiple Trauma Patients
by: Florian J. Schweigert, et al.
Published: (2007-01-01)

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
by: Freeman Daniel J, et al.
Published: (2012-07-01)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
by: Shun Xin Wang-Lin, et al.
Published: (2018-01-01)

Assessment the equivalence of the bioanalogue insulin lizpro biphasic 25 (Geropharm-bio, Russia) and Humalog® Mix 25 (Lilly France, France) using the euglycemic hyperinsulinum clamp method on healthy volonters
by: Alexander Y. Mayorov, et al.
Published: (2018-12-01)

A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab
by: C. Schwabe, et al.
Published: (2023-04-01)

Biological medicinal products: reference and biosimilar products – selected issues
by: Bartosz Kobuszewski
Published: (2021-10-01)

Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia
by: A. Yu. Efremov, et al.
Published: (2023-09-01)

Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers
by: Martínez González J, et al.
Published: (2018-03-01)

Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
by: Eleni Triantafyllidi, et al.
Published: (2022-08-01)

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
by: Stefan Schreiber, et al.
Published: (2020-06-01)

Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants
by: Eleni Pefani, et al.
Published: (2023-04-01)

Pharmacokinetics and pharmacodynamics of low doses of recombinant tissue plasminogen activator to establish a model for biosimilarity comparisons
by: Ulla Derhaschnig, et al.
Published: (2024-08-01)

Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
by: Hasumati Rahalkar, et al.
Published: (2018-09-01)

Comprehensive Mapping and Dynamics of Site-Specific Prolyl-Hydroxylation, Lysyl-Hydroxylation and Lysyl O-Glycosylation of Collagens Deposited in ECM During Zebrafish Heart Regeneration
by: Vivek Sarohi, et al.
Published: (2022-06-01)

Advanced assessment through intact glycopeptide analysis of Infliximab’s biologics and biosimilar
by: Hyejin Kim, et al.
Published: (2022-11-01)

Biosimilar medicines uptake: The role of the clinical pharmacist
by: Roland Nnaemeka Okoro
Published: (2021-03-01)

Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product
by: Singh SK, et al.
Published: (2018-11-01)

The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
by: Sarfaraz K. Niazi
Published: (2023-10-01)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
by: Evelien Moorkens, et al.
Published: (2020-01-01)

Monoclonal antibody usage pattern in a tertiary care center: A retrospective study
by: Shruthi Sridhar, et al.
Published: (2024-08-01)

A Regulatory Perspective on Biosimilar Medicines
by: Marta Agostinho Cordeiro, et al.
Published: (2024-02-01)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
by: Erik Doevendans, et al.
Published: (2019-03-01)

Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01)